Hydroxypyridinones and desferrioxamine inhibit macrophage-mediated LDL oxidation by iron but not by copper.
Lamb
D J
DJ
Dept. of Biochemistry & Physiology, University of Reading, Whiteknights, Reading.
Hider
R C
RC
Leake
D S
DS
D000818:Animals; D003300:Copper / Q000494:pharmacology*; D019327:Copper Sulfate; D000077543:Deferiprone; D003676:Deferoxamine / Q000494:pharmacology*; D005296:Ferrous Compounds / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007502:Iron Chelating Agents / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification / Q000378:metabolism*; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D011728:Pyridones / Q000494:pharmacology*
D005296:Ferrous Compounds; D007502:Iron Chelating Agents; D008077:Lipoproteins, LDL; D011728:Pyridones; D000077543:Deferiprone; C020748:ferrous sulfate; D003300:Copper; D003676:Deferoxamine; D019327:Copper Sulfate